NewMoneyMoves
PerspectivesResearchTerminalsWeekend RWABoard
HomeEarningsEli Lilly and Company FY2026 Q1
Released
FY2026 Q1
Earnings Review
LLY
BEAT

Eli Lilly and Company

Eli Lilly and Company · Pharmaceuticals/Biotech

Thu, April 30, 2026·Before Market Open
Eli LillyGLP-1ObesityPharmaceuticalsEarnings

01Wall Street Consensus

EPS$7.45
Revenue$13.8B

02Earnings Results

EPS$8.55+24.8%
Revenue$19.8B+11.1%
After-Hours ReactionRegular +10%

Key Takeaways

  • Non-GAAP EPS $8.55 — beat consensus $6.85 by +24.8%, +156% YoY
  • GAAP EPS $8.26 — +170% YoY
  • Revenue $19.8B — beat consensus $17.82B by +11.1%, +56% YoY all-time quarterly high
  • Mounjaro revenue $8.66B — +125% YoY (diabetes)
  • Zepbound revenue $4.16B — +80% YoY (obesity)
  • GLP-1 category accounts for roughly two-thirds of total revenue
  • FY2026 revenue guide raised to $82-85B from $80-83B
  • FY2026 non-GAAP EPS guide raised to $35.50-37.00

Key Checkpoints

  • 01Mounjaro (diabetes) + Zepbound (obesity) combined revenue — acceleration from Q4 2025 $7B+ run rate
  • 02GLP-1 supply constraint resolution progress — new manufacturing facility ramp effect
  • 03Zepbound obesity market share — vs Novo Nordisk Wegovy
  • 04Pipeline: orforglipron (oral GLP-1), retatrutide (triple agonist) clinical progress
  • 05Gross Margin 82%+ maintenance — manufacturing scale-up effect
  • 06FY2026 revenue guidance $58-62B trajectory achievement

Upside Catalysts

  • Zepbound indication expansion: obstructive sleep apnea (OSA), NASH/MASH, heart failure expanding TAM to $100B+
  • orforglipron (oral GLP-1): Phase 3 results expected 2026 - injection-to-oral transition game changer
  • retatrutide (GLP-1/GIP/glucagon triple agonist): -25%+ weight loss - next-gen obesity treatment innovation
  • Manufacturing capacity expansion: $20B+ global facility investment accelerating supply constraint resolution
  • Defensive safe haven: healthcare growth stock premium surging amid Iran war escalation, oil spike to $107+, and global equity selloff - institutional rotation into quality pharma

Risk Factors

  • GLP-1 competition intensifying: Novo Nordisk Wegovy/Ozempic + Viking, Amgen and other followers entering
  • Drug pricing regulation: IRA price negotiation scope expansion - Mounjaro potentially subject in future
  • Supply constraint persistence: unrealized revenue potential if demand continues exceeding supply
  • Iran war escalation (4/2 Trump speech: 2-3 more weeks of strikes) - macro uncertainty pressuring high-valuation biotech multiples; S&P Q1 -4.2%, Nasdaq Q1 -7.8%
  • Valuation: Forward P/E 50x+ - significant downside risk if elevated expectations not met amid risk-off environment
Detail

EEPS History (Last 12 Quarters)

Actual EPS vs Consensus — Green Beat · Red Miss

Beat9
Miss3
Beat rate75%

1Final Assessment

Eli Lilly is the frontrunner of the GLP-1 obesity and diabetes treatment revolution and the world's #1 pharma company by market cap at $700B+. Consensus EPS $7.45, Revenue $13.8B. Whether Mounjaro+Zepbound combined revenue accelerates from the Q4 2025 $7B+ run rate is the key question.

The biggest variable is the pace of supply constraint resolution. With demand overwhelmingly exceeding supply, if $20B+ manufacturing facility investments start reflecting in Q1, revenue upside surprise is possible.

Amid the Iran war escalation (Trump's 4/2 primetime speech confirmed 2-3 more weeks of energy facility strikes, Brent crude surging past $107), global equities have entered a severe risk-off phase - S&P 500 Q1 -4.2%, Nasdaq Q1 -7.8%, KOSPI -4.37% single-day crash. In this environment, LLY stands out as a premier defensive growth asset, immune to energy prices and geopolitical supply chain disruptions. Institutional rotation into quality healthcare names is accelerating.

2GLP-1 Franchise

Mounjaro (tirzepatide) — Diabetes:

  • 2025 revenue: $18B+ (estimated)
  • Once-weekly injection, GLP-1/GIP dual agonist
  • US + global launch expansion underway

Zepbound (tirzepatide) — Obesity:

  • 2025 revenue: $8B+ (estimated, year 2 of launch)
  • Weight loss: -20-25% (clinical average)
  • Obstructive sleep apnea (OSA) indication approved (2025)
  • Next indications: NASH/MASH, heart failure, chronic kidney disease

Supply Status:

  • Demand >>> Supply (prescription limits, some dose shortages)
  • $20B+ global manufacturing facility investment in progress
  • New capacity expected to ramp significantly from H1 2026
  • At supply normalization, annual revenue potential of $40B+

3Pipeline & Market Outlook

Next-Gen Pipeline:

  • orforglipron: Oral small molecule GLP-1 receptor agonist
  • Phase 3 ongoing, results expected 2026
  • If successful, game changer for injection-to-oral transition
  • Revenue potential: $10B+
  • retatrutide: GLP-1/GIP/glucagon triple agonist
  • Phase 2 weight loss of -25%+ (highest ever)
  • Phase 3 ongoing
  • Potential to become the next-gen obesity treatment standard

Obesity Treatment Market:

  • 2030 global TAM: $100B+ (Goldman Sachs estimate)
  • Current penetration: <5% — massive growth potential
  • Lilly + Novo Nordisk duopoly but followers (Viking, Amgen) entering

Iran Conflict Impact:

  • Direct impact minimal (unrelated to energy/defense)
  • Indirect: Macro uncertainty pressuring high-valuation growth stock multiples
  • Conversely, healthcare defensive premium may be assigned
Detail

SEPS 서프라이즈 히스토리

Beat9Miss3Beat률 75%

분기별 EPS 컨센서스 대비 서프라이즈(%) — 막대: EPS, 점선: 매출

컨센서스 대비 실제 EPS/매출 서프라이즈 (%)

Comments

Earnings
Earnings Info
SymbolLLY
QuarterFY2026 Q1
Report Date2026-04-30
Report TimeBMO
SectorPharmaceuticals/Biotech
StatusReleased
Wall Street Consensus
EPS$7.45
Revenue$13.8B
Results
Actual EPS$8.55
Actual Revenue$19.8B
After-Hours ReactionRegular +10%
NewMoneyMoves

Global Investment through Themes

Content

ThemesIdeasReportsEarnings

Explore

GuideETFsPerspectivesTelegramNVIDIA PortfolioWeekly ReviewCredit & Leverage

Community

Daily News

Legal

Privacy PolicyTerms of ServiceDisclaimer

© 2026 NewMoneyMoves. All rights reserved.